<SEC-DOCUMENT>0001193125-17-331071.txt : 20171102
<SEC-HEADER>0001193125-17-331071.hdr.sgml : 20171102
<ACCEPTANCE-DATETIME>20171102162755
ACCESSION NUMBER:		0001193125-17-331071
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171030
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171102
DATE AS OF CHANGE:		20171102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
		CENTRAL INDEX KEY:			0001299130
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				161590339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34899
		FILM NUMBER:		171172787

	BUSINESS ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-521-8000

	MAIL ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIFIC BIOSCIENCES OF CALIFORNIA INC
		DATE OF NAME CHANGE:	20050829

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOFLUIDICS INC
		DATE OF NAME CHANGE:	20040729
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d486595d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>October&nbsp;30, 2017 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Pacific
Biosciences of California, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-34899</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">16-1590339</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1305 O&#146;Brien Drive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park, California 94025 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">521-8000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;30, 2017, the Board of Directors (the &#147;Board&#148;) of Pacific Biosciences of California, Inc. (the &#147;Company&#148;) appointed Kathy
Ordo&ntilde;ez, a Class&nbsp;III director on the Board, as the Company&#146;s Chief Commercial Officer and Executive Vice President, effective October&nbsp;30, 2017. On October&nbsp;30, 2017, Ms.&nbsp;Ordo&ntilde;ez resigned from her positions as
chair and a member of the Corporate Governance and Nominating Committee of the Board and as a member of the Compensation Committee of the Board. Ms.&nbsp;Ordo&ntilde;ez remains a member of the Board and chair and a member of the Science and
Technology Committee of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Ordo&ntilde;ez, age 67, has been a member of the Board since December 2014. Ms.&nbsp;Ordo&ntilde;ez brings
more than 30 years of experience in the life sciences and diagnostics industries. Ms.&nbsp;Ordo&ntilde;ez served as Director, <FONT STYLE="white-space:nowrap">non-executive</FONT> Chairman, and Chief Executive Officer of RainDance Technologies, Inc.
from July 2014 to February 2017, which was sold to <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> Laboratories, Inc. in February 2017. From January 2012 until June 2013, Ms.&nbsp;Ordo&ntilde;ez was a Senior Vice President at Quest Diagnostics
Incorporated, a leading provider of diagnostic information services, where she was initially responsible for leading their R&amp;D effort and later provided oversight to multiple businesses commercializing diagnostic products and testing services.
Ms.&nbsp;Ordo&ntilde;ez joined Quest Diagnostics as part of its acquisition in 2011 of Celera Corporation, a leading provider of genetic testing products for HIV resistance, cystic fibrosis and high complexity tissue transplantation. From April 2002
until May 2011, Ms.&nbsp;Ordo&ntilde;ez was the Chief Executive Officer at Celera, and she founded Celera Diagnostics in December 2000. From 1985 until 2000, Ms.&nbsp;Ordo&ntilde;ez held several senior positions at
<FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche, overseeing the formation of Roche Molecular Systems, where she served as President and Chief Executive Officer, and led the wide-scale commercial application of the Polymerase Chain Reaction
(PCR) technology to the research, diagnostic and forensic fields. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Ordo&ntilde;ez does not have a family relationship with any member of the
Board or any executive officer of the Company, and Ms.&nbsp;Ordo&ntilde;ez has not been a participant or had an interest in any transaction with the Company that is reportable under Item 404(a) of Regulation
<FONT STYLE="white-space:nowrap">S-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the press release announcing Ms.&nbsp;Ordo&ntilde;ez&#146;s appointment is attached hereto as
Exhibit 99.1. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensatory Arrangement with Kathy Ordo&ntilde;ez </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the appointment of Ms.&nbsp;Ordo&ntilde;ez to her position as the Company&#146;s Chief Commercial Officer and Executive Vice President,
Ms.&nbsp;Ordo&ntilde;ez will receive, among other things, an annual base salary of $1.00 and will be eligible to receive an annual bonus with a target level of 50% of her base salary. In addition, the Company is recommending, and expects that the
Board will approve, a grant of a stock option to Ms.&nbsp;Ordo&ntilde;ez to purchase 375,000 shares of the Company&#146;s common stock under the Company&#146;s 2010 Equity Incentive Plan, subject to vesting over a four (4)&nbsp;year period at a rate
of one forty-eighth (1/48<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) per month. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the appointment, Ms.&nbsp;Ordo&ntilde;ez
also entered into a Change of Control and Severance Agreement with the Company (the &#147;Severance Agreement&#148;) pursuant to which, if Ms.&nbsp;Ordo&ntilde;ez&#146;s employment is terminated without cause or other than death or disability or
resignation for good reason within 12 months following a change in control, then Ms.&nbsp;Ordo&ntilde;ez will continue to receive 100% of her base salary for six months following from the date of termination of employment, plus immediate vesting
acceleration of 100% of the unvested portion of her then-outstanding equity awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed in the Company&#146;s proxy statement for the
2017 Annual Meeting of Stockholders, employee directors are not compensated for services on the Board in addition to their regular employee compensation. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulation FD Disclosure </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;2, 2017, the Company issued a press release announcing the
appointment of Ms.&nbsp;Ordo&ntilde;ez as the Company&#146;s Chief Commercial Officer and Executive Vice President.&nbsp;A copy of the press release is included as Exhibit 99.1 hereto.&nbsp;This information is intended to be furnished under Item
7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&nbsp;Exhibits. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d486595dex991.htm">Press Release dated November&nbsp;2, 2017 (furnished and not filed herewith solely pursuant to Item 7.01). </A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Pacific Biosciences of California, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Susan K. Barnes</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Susan K. Barnes</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Executive Vice President, Chief Financial Officer and Principal Accounting Officer</B></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: November&nbsp;2, 2017 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d486595dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g486595g72o71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pacific Biosciences Appoints Kathy Ordo&ntilde;ez as Chief Commercial Officer </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MENLO PARK, Calif., November</B><B></B><B>&nbsp;2, 2017</B> &#151; Pacific Biosciences of California, Inc. (NASDAQ:PACB) announced today that Kathy
Ordo&ntilde;ez has been named Chief Commercial Officer and Executive Vice President. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Ordo&ntilde;ez brings more than thirty years of experience
in the life sciences and diagnostics industries, with senior roles at <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche, Celera, Quest Diagnostics and RainDance Technologies. At Roche, Kathy was responsible for the formation of Roche
Molecular Systems, where she served as President and Chief Executive Officer for nine years and led the wide-scale commercial application of the polymerization chain reaction (PCR) technology to the research, diagnostic and forensic fields. At
Celera, she oversaw the establishment of the company&#146;s diagnostic sequencing business, which achieved a leadership position in Sanger sequencing for clinical diagnostic applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I have worked with Kathy since the early days of PCR commercialization, and I am pleased that she has agreed to bring her substantial experience to our
commercial endeavors,&#148; said Michael Hunkapiller, Pacific Biosciences Chairman and CEO. &#147;I am excited to continue to work with her to enhance our commercial capability as we expand our research market presence and begin development of our
programs in the clinical market.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Chief Commercial Officer, Ms.&nbsp;Ordo&ntilde;ez will have senior responsibility for the Company&#146;s sales,
support, and marketing operations and remain a member of its Board of Directors. She will report to Chairman and CEO Michael Hunkapiller. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kathy holds a
Bachelor&#146;s degree in chemistry/physics and a Doctorate of Science (Honorary) from Hartwick College in Oneonta, NY. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Pacific Biosciences
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pacific Biosciences of California, Inc.&nbsp;(NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on
its novel Single Molecule, Real-Time (SMRT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) technology, Pacific Biosciences&#146; products enable: <I>de novo</I> genome assembly to finish genomes in order to more fully identify, annotate
and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively
characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences&#146; technology provides high accuracy, ultra-long reads, uniform coverage, and is the only DNA sequencing technology that
provides the ability to simultaneously detect epigenetic changes. PacBio<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> sequencing systems, including consumables and software, provide a simple, fast, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">end-to-end</FONT></FONT> workflow for SMRT Sequencing. More information is available at&nbsp;<U>www.pacb.com</U>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future
availability, uses, quality or performance of, or benefits of using, products or technologies, the company&#146;s commercial capability or market presence, the suitability of the company&#146;s products for particular applications or markets and
other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences&#146;
control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific
Biosciences&#146; most recent filings with the&nbsp;Securities and Exchange Commission, including Pacific Biosciences&#146; most recent reports on Forms <FONT STYLE="white-space:nowrap">8-K,</FONT> <FONT STYLE="white-space:nowrap">10-K</FONT> and <FONT
STYLE="white-space:nowrap">10-Q,</FONT> and include those listed under the caption &#147;Risk Factors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pacific Biosciences undertakes no obligation
to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nicole Litchfield </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">415.793.6468 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>nicole@bioscribe.com </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trevin Rard </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">650.521.8450 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ir@pacificbiosciences.com </U></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g486595g72o71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486595g72o71.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" !# 1X# 2(  A$! Q$!_\0
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9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
